Accelerates endorsement of Blenrep, groundbreaking therapy for multiple myeloma in UAE
In a significant stride towards enhancing drug safety and expanding treatment options within the country, the Emirates Drug Establishment (EDE) has registered Blenrep (Belantamab Mafodotin) as a treatment for multiple myeloma. This innovative therapy is the first antibody-drug conjugate (ADC) to target B-cell maturation antigen (BCMA), offering a novel approach for patients with relapsed or resistant multiple myeloma[1].
Blenrep's administration enhances operational efficiency as it is administered in a simplified manner, eliminating the need for complex preparatory procedures or hospitalisation[1]. This streamlined approach supports quicker treatment delivery and reduces the burden on healthcare facilities, aligning with the EDE's goal of building a resilient pharmaceutical system that ensures timely access to effective therapies for patients in the UAE.
The rapid registration of Blenrep demonstrates the flexibility and efficiency of the EDE's regulatory procedures, as evidenced by Dr. Fatima Al Kaabi, Director General of the Emirates Drug Establishment[1]. By fast-tracking Blenrep's approval, the UAE joined the ranks of countries such as the UK and Japan, becoming one of the first to provide access to this cutting-edge therapy.
Multiple myeloma, which ranked as the third most common cancer in the UAE in 2023, is a complex and aggressive form of blood cancer. The approval of Blenrep is a major development in the treatment of multiple myeloma, offering hope for patients and their families[1].
The EDE's commitment to the national vision is reinforcing the Establishment's commitment to building a knowledge-based economy driven by research, development, and regulatory excellence. The EDE is working to strengthen the integration between regulatory and industrial pathways, adopting cutting-edge medicines that meet international standards and integrating them into a comprehensive, sustainable pharmaceutical model[1].
Through multi-level partnerships with international manufacturers, the EDE aims to enable the national healthcare system to respond to urgent medical needs, further solidifying the UAE's competitiveness on the global regulatory stage[1]. Prof. Dr. Mahmoud Marashi, Vice President of the Emirates Society of Haematology, views the registration of Blenrep as a strategic milestone aimed at accelerating access to transformative therapies that meaningfully improve patients' lives.
[1] Source: Emirates Drug Establishment press release, [date].
- The recent registration of Blenrep, a novel treatment for multiple myeloma, signifies a significant advancement in the field of medical-conditions like cancer, particularly health-and-wellness in the UAE.
- The simplified administration of Blenrep, an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA), is not only beneficial for patients but also promotes technology within the healthcare sector.
- The EDE's swift approval of Blenrep, a treatment for multiple myeloma, demonstrates its commitment to science and innovation, aligning with global trends in health and news regarding advancements in medical-conditions treatment.
